Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil slows fibroblast growth and collagen production, potentially treating keloids, hypertrophic scars, and connective tissue disorders.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

This report describes a case of prolonged distributive shock attributed to minoxidil overdose, which involved intentional ingestion alongside trauma and NSAIDs, successfully managed with medications and hydration despite persistent low blood pressure.

In this self-controlled comparative study of 16 women with Female Pattern Hair Loss, MMP® with Minoxidil showed a better response in the parietal-vertex regions in less advanced cases compared to standard Minoxidil treatment, though overall effectiveness was similar.

Minoxidil boosts hair growth by targeting adenosine and possibly sulfonylurea receptor 2B.

This review reports that pharmacogenomic variations in the SULT1A1 enzyme significantly influence the response to minoxidil treatment for alopecia, suggesting personalized therapeutic strategies could improve efficacy while emerging pharmaceutical technologies aim to optimize oral minoxidil's absorption and minimize side effects.

This review discusses the emerging evidence for low-dose oral minoxidil in treating various types of alopecia, without providing new clinical results.

In this study, lipo-minoxidil was found to increase vascular endothelial growth factor expression in the skin of C57BL/6 mice more than standard minoxidil formulations.

Minoxidil is an effective and safe treatment for common hair loss when applied to the skin, but more research is needed for optimal use.

In this study, a combination of low-dose minoxidil 0.25 mg and spironolactone 25 mg reduced hair shedding and improved hair density in patients with female pattern hair loss, with mild adverse effects.

Oral minoxidil 7.5 mg for hair loss increases heart rate but not blood pressure.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This study found that morroniside enhanced hair follicle growth and transition through the Wnt/β-catenin signaling pathway in a mouse model, suggesting its potential as a treatment for hair loss.

This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.

In this study, researchers found that the compound BMS-470539 induced a senescence-like state in fibroblasts from systemic sclerosis patients, reducing fibrosis-associated markers in vitro and decreasing skin thickness in a mouse model of skin fibrosis, suggesting a novel therapeutic strategy for managing fibroblast-driven diseases.

This article reviews the history and medical literature on minoxidil, highlighting its approved topical use for hair disorders like androgenic alopecia and potential new applications, such as in yellow nail syndrome and vitiligo treatment alongside phototherapy.

In this study, researchers found that minoxidil sulfate enhances the anti-inflammatory effects of the JAK inhibitor baricitinib in alopecia areata, modulating inflammatory signals and preserving immune privilege features in human hair cells, which suggests potential benefits for combined therapy.

Higher minoxidil doses in dogs cause faster heart rate, lower blood pressure, and heart issues.

This study found that combining AMD3100 and low-dose FK506 significantly improved and accelerated the healing of diabetic wounds in rats, suggesting a promising therapeutic approach for wound care in diabetes.

This study found that minoxidil sulfate and pinacidil did not activate K channel currents in hair follicles, suggesting their effect on hair growth might occur through other mechanisms like increased blood flow.

Minoxidil helps hair growth by improving blood vessel function.

This study demonstrated that genetically engineered, ATP-responsive nanozymes effectively reduce cardiac fibrosis by targeting activated cardiac fibroblasts, resulting in decreased myofibroblast accumulation and improved cardiac function, suggesting that this approach has significant potential for therapeutic applications.

This chapter reviews adverse effects of anti-anginal and beta-blocker drugs, stating that starting a beta-blocker may temporarily affect driving ability, but it reports no new clinical findings.

This article does not provide an abstract or present any new research findings.

This article reviews the proposed mechanism of minoxidil in treating androgenetic alopecia, suggesting it may prolong the anagen phase by modulating cell growth factors and vascular activity, but reports no new results.

This study found that combination therapy with 5% minoxidil and 0.5% anthralin led to hair regrowth in some patients with severe treatment-resistant alopecia areata, but also caused mild to moderate irritant dermatitis in all participants.

This document is informational and does not present new research findings, and it advises consulting personal healthcare providers for medical recommendations.